OTCM
EMMA
Market cap4mUSD
Oct 08, Last price
0.06USD
1D
0.10%
1Q
443.24%
IPO
-99.85%
Name
Emmaus Life Sciences Inc
Chart & performance
P/E
—
P/S
0.34
EPS
—
Div yield, %
—
Shrs. gr., 5y
5.54%
Rev. gr., 5y
-11.68%
Revenues
12m
-25.22%
Net income
-7m
L+16.10%
CFO
-11k
L-99.52%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with sickle cell disease in patients aged five and above, covering both pediatric and adult populations. Furthermore, Emmaus maintains a collaborative arrangement with Kainos Medicine, Inc. for the preclinical advancement of Kainos' proprietary IRAK4 inhibitor, KM10544, which is being explored as a potential anti-cancer therapeutic. Established in 2000 as Emmaus Holdings, Inc., the organization rebranded to Emmaus Life Sciences, Inc. in September 2011 and operates from its headquarters in Torrance, California.
Key people
Yasushi Nagasaki
Chief Financial Officer · since 2020
Chairman of the Board, Chief Executive Officer, Chief Operating Officer · since 2024
Charles Stark
Senior Vice President - Medical Affairs, Clinical, Regulatory · since 2021
Jon Kuwahara
Director · since 2024
Independent Director · since 2020
Legal address
C/O United Corporate Services, Inc.
874 Walker Road
Suite C
Dover, DE 19904
US
874 Walker Road
Suite C
Dover, DE 19904
US
Headquarters
85 Enterprise
Suite 410
Aliso Viejo, CA 92656
US
Suite 410
Aliso Viejo, CA 92656
US
Previous name
CNS Response, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||